Literature DB >> 7429640

Human monocyte chemotaxis: migrating cells are a subpopulation with multiple chemotaxin specificities on each cell.

W Falk, E J Leonard.   

Abstract

Only 20 to 40% of human blood monocytes were capable of responding to chemotaxins in vitro. This limit is not due to restrictions of the in vitro system, but is due to the existence of a migrating subpopulation. Over a wide range, the number of cells migrating toward a given concentration of chemotaxin was directly proportional to the number added to the chemotaxis chamber. These monocytes responded to all of the three stimuli used: human serum-derived C5a, human lymphocyte-derived chemotactic factor, and a synthetic peptide. It was possible to deactivate cells to one attractant, leaving the response to other attractants intact. This suggested that these attractants were recognized by different receptors. Several lines of evidence showed that most migrating cells had receptors for all three chemotaxins tested. Thus, if cells were assayed for migration to one attractant, no additional migration occurred when the remaining cells were assayed for migration to a different attractant. Furthermore, the same cells that had migrated toward one attractant were able to respond to other chemotaxins. We also found that a single attractant attracted as many cells as a combination of two or three attractants. Calculations from these data showed that at least 75% of the migrating monocytes have different receptors for all three attractants.

Entities:  

Mesh:

Year:  1980        PMID: 7429640      PMCID: PMC551223          DOI: 10.1128/iai.29.3.953-959.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Chemotactic deactivation of human eosinophils by the eosinophil chemotactic factor of anaphylaxis (38527).

Authors:  S I Wasserman; D Whitmer; E J Geotzl; K F Austen
Journal:  Proc Soc Exp Biol Med       Date:  1975-01

2.  Abnormal monocyte chemotactic response in cancer patients.

Authors:  D A Boetcher; E J Leonard
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

3.  A human mononuclear leukocyte chemotactic factor: characterization, specificity and kinetics of production by homologous leukocytes.

Authors:  L C Altman; R Snyderman; J J Oppenheim; S E Mergenhagen
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

4.  Demonstration of a receptor on rabbit neutrophils for chemotactic peptides.

Authors:  S Aswanikumar; B Corcoran; E Schiffmann; A R Day; R J Freer; H J Showell; E L Becker
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

5.  Depressed mononuclear leukocyte chemotaxis in thermally injured patients.

Authors:  L C Altman; C T Furukawa; S J Klebanoff
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

6.  A method for staining multiple chemotaxis filters.

Authors:  E J Leonard
Journal:  J Immunol Methods       Date:  1975-11       Impact factor: 2.303

7.  Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.

Authors:  H N Fernandez; T E Hugli
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

8.  Monocyte function in man.

Authors:  M C Territo; M J Cline
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

9.  Role of a peptidase in phagocyte chemotaxis.

Authors:  S Aswanikumar; E Schiffmann; B A Corcoran; S M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

10.  The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase.

Authors:  P A Ward; E L Becker
Journal:  J Exp Med       Date:  1968-04-01       Impact factor: 14.307

View more
  20 in total

1.  Chemotactic factor-induced polarization, receptor redistribution, and locomotion of human blood monocytes.

Authors:  L N Islam; P C Wilkinson
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

2.  Mathematical analysis of cell-target encounter rates in two dimensions. The effect of chemotaxis.

Authors:  E S Fisher; D A Lauffenburger
Journal:  Biophys J       Date:  1987-05       Impact factor: 4.033

3.  Specificity and reversibility of chemotactic deactivation of human monocytes.

Authors:  W Falk; E J Leonard
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

Review 4.  Chemotaxis and methylation in a macrophage cell line.

Authors:  R R Aksamit; P S Backlund
Journal:  Surv Immunol Res       Date:  1983

Review 5.  Chemotaxis: basic aspects of methodology, mechanisms and pathology.

Authors:  B M Czarnetzki; E Kownatzki; M Dierich; P C Frei
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

Review 6.  Heterogeneity of human neutrophil and monocyte chemotactic responsiveness.

Authors:  L Harvath
Journal:  Surv Immunol Res       Date:  1983

7.  Alveolar macrophage dysfunction in malignant lung tumours.

Authors:  E Lemarie; P Carre; M F Legrand; M Lavandier; E Boissinot; M Renoux; G Renoux
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

8.  C5a promotes migration, proliferation, and vessel formation in endothelial cells.

Authors:  Ryuji Kurihara; Kunihiro Yamaoka; Norifumi Sawamukai; Shohei Shimajiri; Koichi Oshita; Sonosuke Yukawa; Mikiko Tokunaga; Shigeru Iwata; Kazuyoshi Saito; Kenji Chiba; Yoshiya Tanaka
Journal:  Inflamm Res       Date:  2010-03-09       Impact factor: 4.575

9.  Chemotactic and phagocytic responses of human alveolar macrophages to activated complement components.

Authors:  S W Richards; P K Peterson; H A Verbrugh; R D Nelson; D E Hammerschmidt; J R Hoidal
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

10.  Only the chemotactic subpopulation of human blood monocytes expresses receptors for the chemotactic peptide N-formylmethionyl-leucyl-phenylalanine.

Authors:  W Falk; L Harvath; E J Leonard
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.